From: Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists?
Canada | Netherlands | Total | |||||
---|---|---|---|---|---|---|---|
n | % | n | % | n | % | ||
Sample | 68 | 100% | 15 | 100% | 83 | 100% | |
Response | 24 | 35% | 9 | 60% | 33 | 40% | |
Sex | Male | 7 | 29% | 3 | 33% | 10 | 30% |
Female | 17 | 71% | 6 | 67% | 23 | 70% | |
Age | 31–40 | 4 | 17% | 1 | 11% | 5 | 15% |
41–50 | 11 | 46% | 4 | 44% | 15 | 45% | |
> 50 | 9 | 38% | 4 | 44% | 13 | 39% | |
Primary practice Setting | Academic setting, university based | 20 | 83% | 9 | 100% | 29 | 88% |
Academic appointment but community based practice | 2 | 8% | 0 | 0% | 2 | 6% | |
Solo community based practice | 2 | 8% | 0 | 0% | 2 | 6% | |
Experience | < 5 years | 4 | 17% | 2 | 22% | 6 | 18% |
6–10 years | 4 | 17% | 2 | 22% | 6 | 18% | |
11–20 years | 9 | 38% | 4 | 44% | 13 | 39% | |
21–30 years | 7 | 29% | 1 | 11% | 8 | 24% | |
Clinical work (% of FTE) | < 50% | 3 | 13% | 1 | 11% | 4 | 12% |
50–75% | 11 | 46% | 5 | 56% | 16 | 48% | |
> 75% | 10 | 42% | 3 | 33% | 13 | 39% | |
New patients each month (n) | 1–3 | 14 | 58% | 8 | 89% | 22 | 67% |
4–6 | 9 | 38% | 1 | 11% | 10 | 30% | |
FU patients each month (n) | 1–5 | 4 | 17% | 0 | 0% | 4 | 12% |
6–25 | 10 | 42% | 5 | 56% | 15 | 45% | |
26–50 | 9 | 38% | 2 | 22% | 11 | 33% | |
> 50 | 1 | 4% | 2 | 22% | 3 | 9% | |
Minimal treatment time after achieving CID | 6 months | 0 | 0% | 4 | 44% | 4 | 12% |
9 months | 1 | 4% | 2 | 22% | 3 | 9% | |
12 months | 12 | 50% | 3 | 33% | 15 | 45% | |
15 months | 2 | 8% | 0 | 0% | 2 | 6% | |
18 months | 3 | 13% | 0 | 0% | 3 | 9% | |
other | 6 | 25% | 0 | 0% | 6 | 18% | |
Discontinuation strategy | immediately stop | 7 | 29% | 1 | 11% | 8 | 24% |
< 6 months tapering | 10 | 42% | 4 | 44% | 14 | 42% | |
6–12 months tapering | 2 | 8% | 1 | 11% | 3 | 9% | |
18–24 months tapering | 1 | 4% | 2 | 22% | 3 | 9% | |
other | 4 | 17% | 1 | 11% | 5 | 15% |